Breast and prostate cancers are the most prevalent forms of cancer amongst women and men respectively. From an ethnic point of view, African-American men are the group with the highest incidence rate of cancer in the United States. Kentucky and Delaware are the U.S. states where the rate of cancer is the highest, while New Mexico and Nevada have the lowest number of new cancer cases per 100,000 inhabitants.
While incidence rates are increasing, cancer death rates have constantly fallen since 1990. Men have a higher risk of mortality from cancer than women and African-Americans are the ethnic group with the highest number of cancer-related deaths per 100,000 population. Lung and bronchial cancer cause the highest number of cancer-related deaths. Approximately 66,020 women and 76,650 men are predicted to die from this type of cancer in 2019. The chance of surviving for a five-year period upon diagnosis has increased from 49 percent in the 1970s to 69 percent as of 2014.
The cancer drug market is among the top pharmaceutical therapeutic areas both in the United States, and worldwide. Expenditure on oncological medicine in the U.S. was worth some 58.4 billion U.S. dollars in 2018. The top cancer drug worldwide is Clegene's Revlimid, generating 8.19 billion U.S. dollars of revenue in 2017. The United States is a top global developer of new cancer drugs, with the largest groups aimed at treating solid tumors, lung cancer, and leukemia.